Independent validation of progression-free survival rate at 9 and 18 weeks (PFSR-18, PFSR-9) as predictor for overall survival (OS) in patients with malignant pleural mesothelioma (MPM): EORTC 08052 study.
Baktiar Hasan
No relevant relationships to disclose
Athanasios G. Pallis
No relevant relationships to disclose
Rabab Mohamed Gaafar
No relevant relationships to disclose
Laurent Greillier
No relevant relationships to disclose
Jan P. Van Meerbeeck
No relevant relationships to disclose
Mary O'Brien
No relevant relationships to disclose